Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 72162-1276

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 72162-1276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

01 (30406488 Figure 01)

01 (30406488 Figure 01)
FDA Label Image

Figure2 (30406488 Figure 02)

Figure2 (30406488 Figure 02)
FDA Label Image

Figure-03 (30406488 Figure 03)

Figure-03 (30406488 Figure 03)
Cumulative Percentage of Patients This text appears to be a graphical representation of the cumulative percentage of patients in different treatment groups. The data seems to indicate the percentage of patients experiencing different levels of change in ADAS-cog (a cognitive assessment) scores from baseline. The treatment groups include a placebo group, a group receiving 5mg/day of Donepezil Hydrochioride Tablets, and a group receiving 10mg/day of the same tablets. The percentages range from 0% to 100% and are plotted against different levels of change from baseline (-15 to +15). The percentages seem to indicate the proportion of patients in each group who experienced various levels of change in their ADAS-cog scores.*
FDA Label Image

Figure-04 (30406488 Figure 04)

Figure-04 (30406488 Figure 04)
FDA Label Image

Figure-05 (30406488 Figure 05)

Figure-05 (30406488 Figure 05)
ADAS-cog Change from Baseline is a measure of clinical improvement in patients taking Donepezil Hydrochloride Tablets. The mean improvement is shown over a 12-week period of drug treatment. The study includes patients taking both 10 mg/day and 5 mg/day doses of Donepezil Hydrochloride Tablets, as well as patients receiving a placebo.*
FDA Label Image

Figure-06 (30406488 Figure 06)

Figure-06 (30406488 Figure 06)
FDA Label Image

Figure-07 (30406488 Figure 07)

Figure-07 (30406488 Figure 07)
FDA Label Image

08 (30406488 Figure 08)

08 (30406488 Figure 08)
FDA Label Image

09 (30406488 Figure 09)

09 (30406488 Figure 09)
FDA Label Image

10 (30406488 Figure 10)

10 (30406488 Figure 10)
FDA Label Image

11 (30406488 Figure 11)

11 (30406488 Figure 11)
FDA Label Image

12 (30406488 Figure 12)

12 (30406488 Figure 12)
FDA Label Image

13 (30406488 Figure 13)

13 (30406488 Figure 13)
FDA Label Image

14 (30406488 Figure 14)

14 (30406488 Figure 14)
FDA Label Image

15 (30406488 Figure 15)

15 (30406488 Figure 15)
FDA Label Image

Label (Lbl721621276)

Label (Lbl721621276)
Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.